News

We hope that everyone is remaining healthy during the COVID-10 outbreak. At Future Diagnostics, we work on tomorrow’s healthcare projects. That is what makes our work interesting. Especially at this time when healthcare is being challenged like this. To prevent the spread of the virus we have taken several measures.

The terms verification and validation are often mixed up; the meanings being often accidentally interchanged or just used for the same purpose. But when overviewing the processes of product verification and validation at our facilities it is noticeable how content and application are similar, but the reasons behind the applications clearly differ. 

Last year was extraordinary. We would like to express our sincerest thanks for your continuous support. We cherish the safety and wellbeing of you, our colleagues, our clients and loved ones. We wish you a happy and healthy New Year and we hope to see you again in 2021.

Be it for determining a Vitamin-D deficiency or the presence of COVID-19 or hiv in clinical specimens; there are immunoassays for measuring each of these specific biomarkers. This blog provides an overview of the different immunoassays present in the current market.

Do you wish to experience our work in IVD product development from the first moment of contact to the realization of your end product? We open our doors for you to witness the procedures and processes, who participate in these processes and our commitment to working according to laws and regulations.

We choose to be transparent and like to share our knowledge with you. Only by showing how we work and think we can offer you a solid partnership. For this reason we created several blogs about subjects from our daily practice. Our professionals will give you insight into our processes and methods to help your business succeed in cooperating with Future Diagnostics.

DIAsource Immunoassays (Louvain-la-Neuve, Belgium), a BioVendor group company, has entered into a strategic agreement with Future Diagnostics (Wijchen, The Netherlands) under which Future Diagnostics will transfer all assets, with the exclusion of IP, related to Free 25OH Vitamin D ELISA product to DIAsource, securing its continued production and sales.

We hope that everyone is remaining healthy during the SARS-CoV-2 outbreak. At Future Diagnostics, we work on tomorrow’s healthcare projects. That is what makes our work interesting. Especially at this time when healthcare is being challenged like this.